MetaCap

Decoy Therapeutics (DCOY) vs Enlivex (ENLV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enlivex is the larger company by market cap ($2.0 million vs $2.0 million), about 1.0 times the size. On valuation, Enlivex trades at a lower trailing P/E (0.0x vs 0.0x for Decoy Therapeutics).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DCOY-48.48%ENLV+242.69%
+823%+366%-90%
Oct 7, 20261 yearNov 20, 2026
DCOY-43.58%ENLV+313.39%
+633%+279%-76%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DCOY versus ENLV key metrics
MetricDCOYENLV
Share price$0.8294$1.05
Market cap$1.98M$2.01M
1-day change-4.68%-11.76%
P/E ratio (TTM)0.030.00
EPS (TTM)$31.19$7,904.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-12.52M$1.24B
52-week high$16.92$434.40
52-week low$0.80$1.00
Distance from 52-week high-95.10%-99.76%
Analyst consensusstrong_buynone
Avg. price target upside+261.71%+7519.05%
Average volume2.17M73.14K
Shares outstanding2.39M1.91M
Employees1134
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Decoy Therapeutics trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).

About Decoy Therapeutics

DCOY stock →

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Enlivex

ENLV stock →

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

DCOY vs ENLV FAQ

Which is bigger, Decoy Therapeutics or Enlivex?

Enlivex (ENLV) is larger, with a market capitalization of $2.01M compared with $1.98M for Decoy Therapeutics (DCOY).

Which has the lower P/E ratio, DCOY or ENLV?

ENLV has the lower trailing P/E at 0.0, versus 0.0 for DCOY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Decoy Therapeutics and Enlivex in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons